Home/Filings/4/0000950170-25-023311
4//SEC Filing

Chi Jeffrey 4

Accession 0000950170-25-023311

CIK 0001774857other

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 4:57 PM ET

Size

7.8 KB

Accession

0000950170-25-023311

Insider Transaction Report

Form 4
Period: 2025-02-14
Chi Jeffrey
Director
Transactions
  • Conversion

    Common Stock

    2025-02-14+133,364133,364 total(indirect: By LLC)
  • Conversion

    Series C Convertible Preferred Stock

    2025-02-141,130,1350 total(indirect: By LLC)
    Common Stock (133,364 underlying)
Footnotes (2)
  • [F1]The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date.
  • [F2]Vickers Venture Co-investment LLC ("Vickers Co-investment") is managed by Vickers Venture Partners (S) Pte. Ltd. which is in turn managed by its directors, being Dr. Jeffrey Chi and Dr. Finian Tan, who collectively exercise sole voting and dispositive power over the securities held by Vickers Co-investment. Each of Vickers Venture Partners (S) Pte. Ltd., Dr. Jeffrey Chi and Dr. Finian Tan disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

Documents

1 file

Issuer

Aardvark Therapeutics, Inc.

CIK 0001774857

Entity typeother

Related Parties

1
  • filerCIK 0001839163

Filing Metadata

Form type
4
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 4:57 PM ET
Size
7.8 KB